| 000 | 00000nam##2200000za#4500 |
| 001 | 9.614224 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20200327132856 |
|---|
| 007 | ta |
|---|
| 008 | 150406|1997||||xxc||||| f|0| 0 eng|d |
|---|
| 020 | |a0-662-26385-5 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH42-2/67-12-1997E |
|---|
| 110 | 1 |aCanada.|bHealth Canada. |bTherapeutic Products Directorate. |
|---|
| 245 | 10|aICH harmonized tripartite guideline: general consideration for clinical trials : |bInternational Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use |
|---|
| 260 | |aOttawa - Ontario : |bHealth Canada. |c1997. |
|---|
| 300 | |a15p. : |btables ; |c28 cm. |
|---|
| 490 | 1 |aTherapeutic Products Directorate guidelines |
|---|
| 563 | |aLoose-leaf |
|---|
| 590 | |a98-38|b1998-09-18 |
|---|
| 776 | 0#|tGeneral considerations for clinical trials |w(CaOODSP)9.573626 |
|---|
| 830 | #0|aTherapeutic Products Directorate guidelines.|w(CaOODSP)9.514729 |
|---|